Last reviewed · How we verify
tiotropium bromide (TIO)
Tiotropium is a long-acting anticholinergic (antimuscarinic) agent that blocks M3 muscarinic receptors on airway smooth muscle to produce sustained bronchodilation.
Tiotropium is a long-acting anticholinergic (antimuscarinic) agent that blocks M3 muscarinic receptors on airway smooth muscle to produce sustained bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma (in combination with inhaled corticosteroids).
At a glance
| Generic name | tiotropium bromide (TIO) |
|---|---|
| Also known as | Spriva® |
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tiotropium binds to muscarinic M3 receptors on bronchial smooth muscle, preventing acetylcholine-induced bronchoconstriction. This results in sustained airway relaxation and improved airflow. The drug is inhaled once daily and provides 24-hour bronchodilation, making it a maintenance therapy for chronic obstructive pulmonary disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma (in combination with inhaled corticosteroids)
Common side effects
- Dry mouth
- Tremor
- Headache
- Urinary retention
- Pharyngitis
Key clinical trials
- Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
- Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
- A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
- Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
- Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)
- A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
- TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |